
Dimitrios Karponis, Khaylen Mistry, Birgitta van Bodegraven, Nick Levell, Zoe Venables.
Declarations

I declare no conflicts of interest.
Why Lentigo Maligna (LM)

Melanoma in situ of rising incidence?
  Australia (2019): 12.2 per 100,000 person years
  US, Minnesota (2014): 13.7 per 100,000 person years

Progression to lentigo maligna melanoma (LMM)
  Lifetime risk: 2-5%\(^4\)-\(^7\)
  Mean time: 28.3 years ([95% CI]: 20.0-40.5)\(^7\)
  Kaplan-Meier disease-specific survival for LM\(^8\):
    5-year: 100%
    10-year: 97.1%

1. Image reproduced from: DermNet NZ.
Why Lentigo Maligna (LM)

Median age at diagnosis: 66-72

Treatment options

- Surgery (WLE, staged excision, Mohs) – 5mm WLE margins? ± MDT
- Imiquimod, radiotherapy, cryotherapy, laser, expectant monitoring
- Localised recurrence at 5y 5-20%

Confocal microscopy

- 59% had subclinical disease >5mm beyond dermoscopic margin
- Confocal mapping changed management in 73% of patients

1. Image reproduced from: DermNet NZ.
Aims

Calculate the crude incidence of LM in England between 2013-2019

Compare survival of patients after LM to those after melanoma

Describe patient characteristics with LM
Methods

The Get Data Out (GDO) program
Openly available (https://www.cancerdata.nhs.uk/getdataout/skin)


Regression analysis (Joinpoint software)

Incidence, net survival, age, gender
LM 2013-2019 - plateauing incidence

18,377 new cases in total (2,625 per year on average)

Joinpoint analysis:

2013-2015:
Annual % Change = 7%
(CI: -9.9 – 27.2)
p=0.23

2015-2019:
Annual % Change = -1%
(CI: -6.0 – 4.1)
p=0.45
Change in crude incidence: Other melanoma *in situ* (face, head and scalp)

3453 new cases in total (491 per year on average)

Annual % change = 7.5%

(CI: 4.9 – 10.3),

p<0.001
Registration practices are unlikely to explain the plateauing incidence of LM

Crude incidence rate (/100,000 py

Year

LM
Other facial MIS
LM + Other facial MIS

2013-2015: Annual % change = 7.1% (CI: -4.4–20.0) p=0.23
2015-2019: Annual % change = 0.2% (CI: -3.0–3.6) p=0.45
Change in crude incidence: Other melanoma *in situ* (all sites)

25682 new cases (3669 per year on average)

Annual % change = 6.4% (CI: 4.7 – 8.2)  
p<0.001
Change in crude incidence: Melanoma (all stages, not in situ)
99054 new cases (14151 per year on average)

Annual % change = 2%
(CI: 1.2 – 2.8)
p<0.001
Crude incidence rates of LM by age and gender

### LM survival data from the GDO program

<table>
<thead>
<tr>
<th></th>
<th>Net 5-year survival, %</th>
<th>Male</th>
<th>Female</th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013-2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>60-69 years</td>
<td>70-79 years</td>
<td>80 years +</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100.6 (98.8-102.5)</td>
<td>103.7 (101.3-106.2)</td>
<td>104.9 (98.1-111.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60-69 years</td>
<td>70-79 years</td>
<td>80 years +</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100.4 (98.7-102.2)</td>
<td>102.4 (99.9-104.8)</td>
<td>&gt;103.1 (.h)</td>
</tr>
</tbody>
</table>

Net 5-year (%) survival for melanoma: 89.3 (88.7-89.8)
Limitations

Report-level data

LM registration based on histopathological data or MDT discussions
  Topically treated (without biopsy) or untreated LMs not included

Patients treated privately likely underrepresented
  Private laboratories not required to submit data

Crude incidence rates
Summary - LM

This is the largest series of high-quality data on LM in the world
Plateauing incidence (in contrast with international data)\(^1\)\(^-\)\(^6\)
2020 data (Covid-19)
More common in men and with old age
Excellent 5-year survival rates (≥100%)
Survival advantage
    Fewer frail patients seeking care, being referred, undergoing biopsy or surgery

Current practice and treatment options?

3. Čelakovská et al.*Acta Med (Hradec Kralove)*, 2020 (Czech Republic)
Acknowledgements

• Prof. Nick J Levell
• Assoc. Prof. Zoe Venables
• Dr Khaylen Mistry
• Dr Birgitta van Bodegraven
How does recording work for GDO?

• GDO publishes cancer statistics produced by NDRS (formerly PHE) from data in the cancer registry, on:
  • Patient characteristics
  • Incidence
  • Treatment
  • Survival rates
  • Routes to diagnosis.

• Why until 2020?
  • Covid
  • Later data not available yet.